← Back to Clinical Trials
Recruiting NCT06460805

axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Axial Spondyloarthritis
Sponsor NHS Greater Glasgow and Clyde
Study Type INTERVENTIONAL
Phase N/A
Enrollment 62
Sex ALL
Min Age 16 Years
Max Age N/A
Start Date 2024-04-25
Completion 2025-08-01
Interventions
Partial enteral nutrition

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

People with axial spondyloarthritis (axSpA) often have intestinal inflammation and intestinal microbiome dysbiosis, with some similarities to Crohn's-like inflammatory bowel disease (IBD) gut inflammation. However, research has not addressed whether Partial Enteral Nutrition (PEN), a diet formed of a liquid formula and some solid whole foods, which is effective at inducing remission in IBD, may influence the dysbiotic microbiome and inflamed, hyperpermeable intestine of axSpA patients, and whether these changes may be accompanied by alterations in systemic markers of inflammation. Thus, there is a need to determine the effects of PEN on these aspects in axSpA patients. In this study, the investigators intend to trial a 2-week course (with optional additional 2-week extension) of a PEN diet in people with active axSpA disease. A group of healthy volunteers following the same diet will act as a control.

Eligibility Criteria

Eligibility Criteria for Participants with axSpA Inclusion criteria. Participants will fulfil ALL of the following: * Diagnosis of axSpA (fulfilling the ASAS criteria) * Active disease (BASDAI score ≥4) on day of study visit * Stable on treatment \[defined as (1) no major change to therapy (change in treatment type) in the preceding 3 months AND (2) no minor change in therapy (adjustment of treatment dosage) in the preceding 1 month\] * Age ≥ 16 years * Willing and able to give informed written consent. Exclusion. Participants will have NONE of the following: * Pregnancy or breastfeeding * Prior diagnosis of IBD * Recipient of chemotherapy/immunotherapy/radiotherapy in prior 3 months * Recent systemic antibiotic use (within last 1 month) * Current eating disorder * Food allergy incompatible with diet (e.g. cow's milk allergy) * Following a vegan diet * Major surgery in prior 3 months or planned in forthcoming 3 months. * Unable or unwilling to give informed consent * Unable or unwillin

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}